0001005201-20-000025.txt : 20200403
0001005201-20-000025.hdr.sgml : 20200403
20200403185007
ACCESSION NUMBER: 0001005201-20-000025
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20200402
FILED AS OF DATE: 20200403
DATE AS OF CHANGE: 20200403
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Bukofzer Stan
CENTRAL INDEX KEY: 0001663041
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-13111
FILM NUMBER: 20775342
MAIL ADDRESS:
STREET 1: C/O OCERA THERAPEUTICS
STREET 2: 525 UNIVERSITY AVENUE, SUITE 610
CITY: PALO ALTO
STATE: CA
ZIP: 94301
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Assertio Therapeutics, Inc
CENTRAL INDEX KEY: 0001005201
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 943229046
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 100 SOUTH SAUNDERS RD
STREET 2: SUITE 300
CITY: LAKE FOREST
STATE: IL
ZIP: 60045
BUSINESS PHONE: (224) 419-7106
MAIL ADDRESS:
STREET 1: 100 SOUTH SAUNDERS RD
STREET 2: SUITE 300
CITY: LAKE FOREST
STATE: IL
ZIP: 60045
FORMER COMPANY:
FORMER CONFORMED NAME: DEPOMED INC
DATE OF NAME CHANGE: 19970408
4
1
wf-form4_158595418892276.xml
FORM 4
X0306
4
2020-04-02
0
0001005201
Assertio Therapeutics, Inc
ASRT
0001663041
Bukofzer Stan
ASSERTIO THERAPEUTICS, INC.
100 SOUTH SAUNDERS ROAD, SUITE 300
LAKE FOREST
IL
60045
0
1
0
0
SVP, Chf Scitfc & Tech Officer
Common Stock
2020-04-02
4
M
0
25370
0
A
70349
D
Common Stock
2020-04-02
4
F
0
7433
0
D
62916
D
Restricted Stock Units
2020-04-02
4
M
0
25370
0
D
2021-04-02
Common Stock
25370.0
40584
D
Represents shares of common stock withheld for payment of taxes upon the vesting of restricted stock units.
Each restricted stock unit represents a contingent right to receive one share of the registrant's common stock.
These Restricted Stock Units are scheduled to vest 27.78% on April 2, 2019, 27.78% on April 2, 2020 and 44.44% on April 2, 2021.
The derivative securities were granted to the reporting person, and were not sold to the reporting person. As such, the reporting person did not pay any consideration for the derivative securities.
/s/ Jennifer Hipelius, attorney in fact
2020-04-03